Divestment

Cardior

Cardior develops RNA-based therapies for cardiovascular diseases, aiming to halt or reverse heart failure progression.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 5
Entry: 2017
Exit: 2024
Website: Cardior

Cardior

Responsible Partner

Christoph Broja

Christoph Broja

Partner

News

Do You Want to Know More?

We are eager to explore how we can achieve great things together.